Physician profile
John J Cote
NPI 1336299320
$235,505.22
in general payments reported to CMS, 2019-2025
36 companies · $8,854 in 2025
The $8,854 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133K · 2020: $36K · 2021: $29K · 2022: $11K · 2023: $16K · 2024: $2,377 · 2025: $8,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $8,000 · Travel and Lodging: $4,234 · Food and Beverage: $2,068 · Education: $87.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,350.00 |
| Consulting Fee | $8,000.00 |
| Travel and Lodging | $4,234.31 |
| Food and Beverage | $2,067.60 |
| Education | $87.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $189,681.50 | 2019-2024 | Liletta, Ubrelvy, Orilissa |
| Pfizer INC. | $35,202.64 | 2019-2024 | |
| Virtual Incision Corporation | $8,042.52 | 2025 | Mira |
| Astellas Pharma US INC | $415.17 | 2022-2025 | Veozah, Prograf |
| Sumitomo Pharma America, INC. | $280.34 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $231.22 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.03 | 2019-2025 | |
| Organon LLC | $176.65 | 2022-2025 | Nexplanon, Jada System |
| Exeltis, USA INC. | $174.16 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $160.03 | 2023-2025 | |
| Biogen, INC. | $133.99 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $77.10 | 2019-2022 | |
| Agile Therapeutics, INC. | $72.89 | 2021-2023 | Twirla |
| Vertex Pharmaceuticals Incorporated | $65.94 | 2025 | |
| Medtronic, INC. | $62.81 | 2022-2025 | Truclear |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $51.26 | 2019 | |
| Channel Medsystems, INC. | $48.57 | 2023 | |
| Lilly USA, LLC | $37.66 | 2025 | Zepbound |
| Lupin INC. | $37.46 | 2019-2020 | |
| Coopersurgical, INC. | $33.70 | 2019-2025 | Paragard T 380a |
| Roche Diagnostics Corporation | $33.06 | 2019-2021 | |
| Novo Nordisk INC | $31.85 | 2022-2023 | Wegovy |
| Hologic Sales and Service, LLC | $29.83 | 2024 | Myosure Tissue Removal Device, Novasure |
| Dexcom, INC. | $27.07 | 2025 | Dexcom G6 Transmitter |
| Covidien LP | $21.71 | 2019 | |
| Smith+Nephew, INC. | $20.50 | 2023 | Pico |
| Pacira Pharmaceuticals Incorporated | $20.34 | 2023 | Exparel |
| Medicem INC. | $18.05 | 2022 | |
| Mylan Pharmaceuticals INC. | $17.77 | 2021 | |
| Meditrina | $16.02 | 2022 | |
| Northgate Technologies, INC. | $14.65 | 2023 | Nti Branded Other (Nti) |
| Avion Pharmaceuticals | $14.36 | 2022 | |
| Merck Sharp & Dohme LLC | $13.67 | 2023 | Gardasil 9 |
| Convatec INC. | $13.56 | 2023 | |
| Boston Scientific Corporation | $13.21 | 2019 | |
| Allergan, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.